- Oops!Something went wrong.Please try again later.
WALTHAM, Mass., Aug. 13, 2019 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc., (ELOX) a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics to treat cystic fibrosis, cystinosis, inherited retinal disorders, and other diseases caused by nonsense mutations limiting production of functional proteins, today announced that two abstracts will be presented at the American Society of Nephrology (ASN) Kidney Week 2019 in Washington, D.C. November 5 -10, 2019.
“We are pleased to be presenting the results of our completed renal impairment study to the scientific community at the American Society of Nephrology Kidney Week. We believe these results support expanding our research in the kidney beyond cystinosis into other areas such as autosomal dominant polycystic kidney disease where there is a high prevalence of nonsense mutation patients,” said Dr. Gregory Williams, Chief Operating Officer of Eloxx Pharmaceuticals. “We are rapidly advancing our Phase 2 programs for ELX-02 in cystic fibrosis and cystinosis and we look forward to reporting top line data from both of these programs later this year.”
“Understanding the renal clearance of ELX-02 provides important information about the appropriate dose adjustments for patients with renal impairment or increased clearance,” said Dr. Tom Haverty, Consulting Nephrologist to Eloxx Pharmaceuticals. “The daily doses of ELX-02 currently being studied in the Phase 2 programs are consistent with those evaluated in Phase 1 and provide steady state exposures shown to be efficacious and safe in animal models.”
The details for the two oral ELX-02 presentations are:
Poster Session Presentation Title: “An open label-single dose, parallel-group study to evaluate the effects of renal impairment on the pharmacokinetics of ELX-02: Results from subjects with mild and moderate renal impairment”
Poster Board #: TH-PO368
Presenter: Dr. Gregory Williams, Chief Operating Officer, Eloxx Pharmaceuticals
Time: November 7, 2019 from 10:00 a.m. – 12:00 pm ET
Poster Session Presentation Title: “Cystinosis nonsense mutation read-through mediated by ELX-02 restores protein function using in vitro and in vivo models” Poster Board #: TH-PO813
Presenter: Dr. Matthew Goddeeris, Eloxx Pharmaceuticals
Time: November 7, 2019 from 10:00 a.m. – 12:00 pm ET
About Eloxx Pharmaceuticals
Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel RNA-modulating drug candidates (designed to be eukaryotic ribosomal selective glycosides) that are formulated to treat rare and ultra-rare premature stop codon diseases. Premature stop codons are point mutations that disrupt protein synthesis from messenger RNA. As a consequence, patients with premature stop codon diseases have reduced or eliminated protein production from the mutation bearing allele accounting for some of the most severe phenotypes in these genetic diseases. These premature stop codons have been identified in over 1,800 rare and ultra-rare diseases. Read-through therapeutic development is focused on extending mRNA half-life and increasing protein synthesis by enabling the cytoplasmic ribosome to read through premature stop codons to produce full-length proteins. Eloxx’s lead investigational product candidate, ELX-02, is a small molecule drug candidate designed to restore production of full-length functional proteins. ELX-02 is in the early stages of clinical development focusing on cystic fibrosis and cystinosis. ELX-02 is an investigational drug that has not been approved by any global regulatory body. Eloxx’s preclinical candidate pool consists of a library of novel drug candidates designed to be eukaryotic ribosomal selective glycosides identified based on read-through potential. Eloxx recently announced a new program focused on rare ocular genetic disorders. Eloxx is headquartered in Waltham, MA, with operations in Rehovot, Israel. For more information, please visit www.eloxxpharma.com.
This press release contains forward-looking statements, which are generally statements that are not historical facts. Forward-looking statements can be identified by the words "expects," "anticipates," "believes," "intends," "estimates," "plans," "will," "outlook" and similar expressions. Forward-looking statements are based on management's current plans, estimates, assumptions and projections, and speak only as of the date they are made. We undertake no obligation to update any forward-looking statement in light of new information or future events, except as otherwise required by law. Forward-looking statements involve inherent risks and uncertainties, most of which are difficult to predict and are generally beyond our control. Actual results or outcomes may differ materially from those implied by the forward-looking statements as a result of the impact of a number of factors, including: the development of the Company’s read-through technology; the approval of the Company’s patent applications; the Company’s ability to successfully defend its intellectual property or obtain necessary licenses at a cost acceptable to the Company, if at all; the successful implementation of the Company’s research and development programs and collaborations; the Company’s ability to obtain applicable regulatory approvals for its current and future product candidates; the acceptance by the market of the Company’s products should they receive regulatory approval; the timing and success of the Company’s preliminary studies, preclinical research, clinical trials, and related regulatory filings; the ability of the Company to consummate additional financings as needed; as well as those discussed in more detail in our Annual Report on Form 10-K and our other reports filed with the Securities and Exchange Commission.
SOURCE: Eloxx Pharmaceuticals, Inc.